SCHEDULE: 3i, LP Updates Beneficial Ownership in Valion Bio, Inc.

3i, LP and associated entities have filed an amendment to their Schedule 13G, disclosing a 9.9% beneficial ownership stake in Valion Bio, Inc.

Summary

• 3i, LP, Tumim Stone Capital LLC, 3i Management LLC, and Maier Joshua Tarlow filed an amendment to their Schedule 13G regarding their holdings in Valion Bio, Inc.
• The reporting persons collectively hold 307,526 shares of common stock, representing a 9.9% ownership stake.
• Beneficial ownership is calculated based on 2,877,926 shares of common stock outstanding as of March 17, 2026.
• Holdings include direct shares, warrants, and convertible notes/preferred stock, all subject to a 9.99% beneficial ownership limitation (Blocker).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure regarding institutional ownership, which is standard for publicly traded companies with complex capital structures.

Positives

• The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Negatives

• The significant reliance on convertible instruments and warrants creates a complex capital structure that may lead to future dilution for existing shareholders.

Risks

• The 9.99% ownership limitation (Blocker) restricts the ability of the reporting persons to convert their holdings into common stock beyond the specified threshold.
• Potential for future dilution of common stock if warrants and convertible securities are exercised or converted.

Future Outlook

The filing does not provide a forward-looking business outlook for the issuer, as it is a disclosure of beneficial ownership by an institutional investor.

Industry Context

StockSavvy.ai notes that this filing reflects typical institutional investment activity in small-cap biotechnology firms, where investors often utilize convertible debt and warrants to manage risk while maintaining a significant equity position.

Comparison to Industry Standards

• The use of 9.99% ownership blockers is a standard practice for institutional investors in small-cap companies to avoid triggering change-of-control provisions or regulatory thresholds.
• The structure of holding a mix of common stock, warrants, and convertible preferred stock is common in biotech financing to provide liquidity and upside potential.

Stakeholder Impact

• Existing shareholders should be aware of the potential for dilution from the conversion of the reported warrants and convertible notes.

Next Steps

• The reporting persons will continue to monitor their holdings and file further amendments if there are material changes to their beneficial ownership.

Key Dates

Keywords

Valion Bio, Schedule 13G, Beneficial Ownership, 3i LP, Tumim Stone Capital, Convertible Securities, Warrants